Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 2,401–2,500 of 4,108
High Prevalence of Vertebral Fracture in a Very Elderly Community-Dwelling: “Longevous Project”
Bastos, L. A., Tavares, D. R. B., Okazaki, J. É. F., Gazoni, F. M., Fonte, F. K., Maeda, S. S., Lazaretti‐Castro, M., Cendoroglo, M. S., & Santos, F. C. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.05.004 · Cited by 5
Choi, H. G., & Kong, G. (2019) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22365 · Cited by 9
Wang, Y., Yu, S., Hsu, C., Tsai, C.-J., & Cheng, T. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05201-5 · Cited by 5
Liu, Y., Wang, L., Su, Y., Brown, J. K., Yang, R., Zhang, Y., Duanmu, Y., Guo, Z., Zhang, W., Yan, C. X., et al. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00721-8 · Cited by 7
Association Between FGF-23 Levels and Risk of Fracture in Women With Systemic Sclerosis
Cantero-Nieto, L. M., Álvarez-Cienfuegos, A., García, J. A., Ríos-Fernández, R., Robledo, G., & Ortego‐Centeno, N. (2020) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2020.05.010 · Cited by 6
Wehbeh, A., Phatharacharukul, P., & Fayad, N. F. (2020) · Advances in Preventive Medicine · doi:10.1155/2020/7128932 · Cited by 6
“Making a diagnosis of osteoporosis is important because it is a known risk factor for bone fractures, and patients with osteoporosis should receive appropriate treatment [10].”
BackgroundValue of Screening for Osteoporosis among Children with Juvenile Idiopathic Arthritis
Hassan, A.-E. A., Rayan, M. M. M., Abdel-Aziz, T. M., et al. (2020) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2020.112406 · Cited by 5
“Table (1): Baseline characteristics among patients with JIA versus controls”
BackgroundLiu, C. S., Feasel, A. L., Kline, G. A., & Billington, E. O. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05823-8 · Cited by 5
Burian, E., Grundl, L., Greve, T., Junker, D., Sollmann, N., Löffler, M. T., Makowski, M. R., Zimmer, C., Kirschke, J. S., & Baum, T. H. (2021) · Diagnostics · doi:10.3390/diagnostics11020240 · Cited by 5
“A precise and valid diagnostic algorithm should be established identifying subjects at risk for an osteoporotic fracture, to enable the clinician to initiate medication adjustments at an early stage [4,7,8].”
BackgroundWen, Z., Ding, N., Chen, R., Liu, S., Wang, Q., Sheng, Z., & Liu, H. (2021) · Endocrine · doi:10.1007/s12020-021-02724-y · Cited by 5
Spinal Care in the Aging Athlete
Kamalapathy, P. N., & Hassanzadeh, H. R. (2021) · Clinics in Sports Medicine · doi:10.1016/j.csm.2021.04.003 · Cited by 5
Does Superior Bone Health Promote a Longer Lifespan?
Dayer, S. R., Mears, S. C., Pangle, A. K., Mendiratta, P., Wei, J. Y., & Azhar, G. (2021) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/21514593211036231 · Cited by 5
“Beginning around the fifth decade of life, maintaining bone health becomes a major health concern due to an increased risk of developing osteoporosis and hence an increased risk of fractures.(13) Osteoporosis is characterized by loss of bone density due to deterioration of bone tissue, which is a result of biological…”
BackgroundAnalysis of type I osteoporosis animal models using synchrotron radiation
Kim, S., Jang, S.-H., Ahn, J., Lee, S., & Lee, O. (2021) · Microscopy Research and Technique · doi:10.1002/jemt.23911 · Cited by 5
Braz, R. R. S., Campos, S. L., Wanderley, D., Antonino, G. B., Batista, P. K. A., Guerino, M. R., Rodrigues, F. T. M., Alves, K. F. P., Duarte, J., Silva, D. D. A., et al. (2022) · Biology · doi:10.3390/biology11020266 · Cited by 11
Pharmaceutical Treatments of Osteoporosis
Phipps, R. J., Mitlak, B., Burr, D. B., & Allen, M. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813259-3.00021-x · Cited by 7
Clinical Evaluation of a Phalangeal Bone Mineral Density Assessment System
Patel, R., Blake, G. M., Panayiotou, E., et al. (2010) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2010.04.001 · Cited by 5
Inpatient procedures in elderly women: An analysis over time
Oliphant, S. S., Ghetti, C. C., McGough, R. L., Wang, L., Bunker, C. H., & Lowder, J. L. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.04.019 · Cited by 5
Managing Asthma in Older Adults
Rance, K. S., & O’Laughlen, M. C. (2013) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2013.11.009 · Cited by 5
Interprofessional care for patients with osteoporosis in a continuing care retirement community
Masterson, J., Woodall, T., Wilson, C. G., Ray, L., & Scott, M. A. (2016) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2016.01.004 · Cited by 6
Borba-Pinheiro, C. J., Dantas, E. H. M., Vale, R. G. D. S., et al. (2016) · UNESP Institutional Repository (São Paulo State University) · Cited by 5
Should women be screened for osteoporosis at midlife?
de Villiers, T. J. (2018) · Climacteric · doi:10.1080/13697137.2017.1406914 · Cited by 5
Shim, K., & Yeul, J. (2018) · Integrative Medicine Research · doi:10.1016/j.imr.2018.06.006 · Cited by 6
The Relationship of Peak Bone Mass, Aging, and Bone Loss to Osteoporosis and Fragility Fractures
Borrelli, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-94202-5_1 · Cited by 8
Murad, R., Mahboob, T., Rehman, R., & Baig, R. (2019) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.35.2.714 · Cited by 5
Role of calcium and vitamin D in prevention and treatment of osteoporosis
Novikov, P. I., & Moiseev, S. V. (2019) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2019-2-70-76 · Cited by 7
Prevalence and Factors Associated with Low Bone Mass and Osteoporosis in Syrian Postmenopausal Women
Hijazi, N., & Alourfi, Z. (2019) · Mathews Journal of Case Reports · doi:10.30654/mjcr.10058 · Cited by 5
“Hence the importance of early detection by conducting periodic surveys and modifying the adjustable risk factors associated with bone [3] low mineral density is the single best predictor of fracture risk in asymptomatic postmenopausal women [5,6], Dual-energy x-ray absorptiometry (DXA) of the hip and spine is the “gol…”
BackgroundPostmenopausal Osteoporosis: A Mini Review
Shuai, Y., Zhang, Z., Guo, T., Yang, R., Lei, J., & Liu, W. (2019) · EMJ Rheumatology · doi:10.33590/emjrheumatol/10311765 · Cited by 5
Kanis, J. А., McCloskey, E. V., Harvey, N. C., & Leslie, W. D. (2018) · Wiley eBooks · doi:10.1002/9781119266594.ch41 · Cited by 5
Calcium Supplementation and Coronary Artery Disease: A Methodological Confound?
Wallace, T. C., & Weaver, C. M. (2019) · Journal of the American College of Nutrition · doi:10.1080/07315724.2019.1681202 · Cited by 5
“The National Osteoporosis Foundation (NOF) has published clinical guidelines for the prevention and treatment of osteoporosis.((10)) A cornerstone to these guidelines is obtaining the recommended intake for calcium (1000mg/d for men 50 to 70 years; 1200mg/d for women 51þ years and men 71þ years), incorporating supplem…”
BackgroundMethodGittoes, N. J. L., & Eastell, R. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198851899.003.0006 · Cited by 5
Dubale, N. M., Kapron, C. M., & West, S. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192315866 · Cited by 5
Ghazaiean, M., Maleki, I., Mousavi, T., Najafi, B., & Moosazadeh, M. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01909-3 · Cited by 8
“The initiatives aimed at preventing bone fractures are highly significant due to their increasing global influence resulting from an aging population [11, 12].”
Maraş, E., Arıcıoğlu, B., Polat, H. B., Arpa, M., Günaçar, D. N., & Köse, T. E. (2025) · International Endodontic Journal · doi:10.1111/iej.70066 · Cited by 5
The transition from preclinical to clinical obesity: the importance of a borderline stage
Maldonado-Arvizu, J. E., Rios-Verdugo, P. V., Díaz‐Villanueva, J. F., Chimal‐Vega, B., Vique‐Sánchez, J. L., & García‐González, V. (2026) · Clinical Science · doi:10.1042/cs20256728 · Cited by 6
“In bone health, osteopenia represents a reduction in bone mineral density that is less severe than osteoporosis, yet it confers a significantly elevated risk of developing the latter condition [106].”
Júnior, J. R. A. D. Q., Cartaxo, M. F. D. S., Paz, S. T., et al. (2022) · Revista Brasileira de Ortopedia · doi:10.1055/s-0041-1741023 · Cited by 4
Fahrenholtz, S. J., Long, J. R., WHITAKER, M. D., & Sensakovic, W. F. (2022) · Medical Physics · doi:10.1002/mp.16057 · Cited by 5
Role of resistance training in bone macro and micro damages in an estrogen absence animal model
Pisani, G. F. D., Stotzer, U. S., Marqueti, R. D. C., Rodrigues, M. F. C., Biffe, B. G., Silva, K. A., Fabrício, V., Rosen, C. J., & Selistre-de-Araújo, H. S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121417 · Cited by 6
Aynaszyan, S., Devia, L. G., Parry, M. W., Badve, S. A., & DelSole, E. M. (2023) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000001466 · Cited by 6
T -score discordance between hip and lumbar spine: risk factors and clinical implications
Chiang, M.-H., Jang, Y.-C., Chen, Y., Chan, W. P., Lin, Y., Huang, S.-W., & Kuo, Y. (2023) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x231177147 · Cited by 7
Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe
Davenport, C., Gravel, P., Wang, Y., Williams, S. A., Wieland, A., & Mitlak, B. (2024) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-024-00616-7 · Cited by 6
“Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture [12–14].”
BackgroundLi, W., Zhang, Z., Li, Y., Wu, Z., Wang, C., Huang, Z., Ye, B., Jiang, X., Yang, X., & Shi, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1443235 · Cited by 6
Beyond Calcium: Current Trends of Supplementation for Bone Health
Naik, R. R., Tan, S., & Selomulya, C. (2024) · Food Reviews International · doi:10.1080/87559129.2024.2440482 · Cited by 6
“[6,7] Different broad-spectrum compounds (apart from the traditional calcium supplements) including nutrients and trace elements have been found to show synergistic effects in maintaining bone density and have provided insights into more sustainable alternatives to conventional bone…”
The Aging Patient with Cystic Fibrosis
Sullivan, L., Mingora, C. M., & Flume, P. A. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01207-3 · Cited by 6
Zhao, C., Li, Q., Jin, P., et al. (2025) · Inflammation Research · doi:10.1007/s00011-025-02096-3 · Cited by 4
“Accord - ing to the International Osteoporosis Foundation (IOF), an osteoporosis-related fracture occurs every three seconds worldwide, often leading to prolonged recovery, complica - tions, and in severe cases, long-term disability [2 ].”
Cho, S. W., Hong, N., Kim, K. M., Lee, Y. H., Kim, C. O., Kim, H. C., Rhee, Y., Chen, B. H., Leslie, W. D., & Cummings, S. R. (2025) · npj Aging · doi:10.1038/s41514-025-00271-8 · Cited by 5
“High risk FRAX probabilities were de fi ned as FRAX major osteoporotic fracture probability ≥ 20% or FRAX hip fracture probability ≥ 3% 30 .”
Vecchi, V. L. (2015) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.1000438 · Cited by 4
Hagen, G., Wisløff, T. F., & Kristiansen, I. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3495-9 · Cited by 5
Panoramic Radiomorphometric Indices of Mandible: Biomarker for Osteoporosis
Govindraju, P., Kumar, T. S. M., Chandra, P., Balaji, P., & Sowbhagya, M. B. (2017) · Biomarkers in disease · doi:10.1007/978-94-007-7693-7_13 · Cited by 4
Modi, A., Ebeling, P. R., Lee, M. S., et al. (2017) · Bone Reports · doi:10.1016/j.bonr.2017.09.003 · Cited by 4
HCV co-infection among people living with HIV Is associated with Higher fracture risk
Pramukti, I., Liu, H.-Y., Chen, C., Chen, Y., Yeh, C., Fetzer, S. J., Ibrahim, K., Tai, T., Ko, W., & Ko, N. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.06.020 · Cited by 7
Park, Y. H., Cho, H. W., Choi, J. W., et al. (2021) · Foot & Ankle International · doi:10.1177/1071100721996262 · Cited by 4
Fujihara, N., Fujihara, Y., Hamada, S., Yoshida, M., & Tsukushi, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248188 · Cited by 4
“We also hypothesized that the therapeutic intervention would be effective in preventing new fragility fractures, as observed in previous studies [12, 13], and if a similar therapeutic effect is observed in cancer patients, then treating osteoporosis may also improve cancer treatment outcomes.”
BackgroundGriffin, J. S., Dent, S. C., & Berger, S. M. (2021) · American Journal of Human Biology · doi:10.1002/ajhb.23583 · Cited by 5
Kamkwalala, A. R., Garg, A., Roy, U. B., Matthews, A. M., Castillo‐Mancilla, J., Lake, J. E., Sebastiani, G., Yin, M. T., Brown, T. T., Kamer, A. R., et al. (2021) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2021.0059 · Cited by 4
“111 The World Health Organization Fracture Risk Assessment Tool (FRAX; www.shef.ac.uk/ FRAX) has been found to underestimate fracture risk in PWH. 112,113 Indeed, subclinical vertebral fractures can be discovered in patients with spinal x-rays who do not meet criteria for osteoporosis by FRAX.”
Bahat, G., Çatıkkaş, N. M., Yavuz, D. G., Borman, P., Güzel, R., & Reginster, J. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-01038-w · Cited by 9
Kobes, T., Sweet, A. A. R., Verstegen, S. B. H., Houwert, R. M., Veldhuis, W. B., Leenen, L. P. H., de Jong, P. A., & van Baal, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030472 · Cited by 5
“Many patients at risk for osteoporosis are overlooked, as screening is recommended mainly in the elderly or in patients who already sustained an adult age fracture [6].”
BackgroundOlarte, C. M., Salazar, A. M. L., Feldman, J. T., et al. (2022) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/21514593221118182 · Cited by 4
“Treatment of Osteoporosis states that people over 50 years of age with a hip fracture should institute a risk assessment and preventive measures for the appropriate treatment for osteoporosis, as indicated.(15) However, it has been seen that medications for the treatment of osteoporosis have been underused in clinical…”
BackgroundLack of Bone Mineral Density Testing in Men With Hypogonadism: A Clinical Conundrum
Goettemoeller, T., Bena, J., & Pantalone, K. M. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac129 · Cited by 5
Sakr, M. F. (2022) · Springer eBooks · doi:10.1007/978-3-031-07418-9_6 · Cited by 6
Jeihooni, A. K., Rakhshani, T., Khiyali, Z., Ebrahimi, M. M., & Harsini, P. A. (2022) · BMC Women s Health · doi:10.1186/s12905-022-01953-1 · Cited by 11
Bone mineral density, nutrient intake, and physical activity among young women from Uganda
Heffron, R. A., Muwonge, T. R., Boyer, J., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01155-0 · Cited by 4
Jadzic, J. S., Zagorac, S., Djuric, M. P., & Djonić, D. (2022) · International Orthopaedics · doi:10.1007/s00264-022-05602-y · Cited by 4
“On the other side, osteoporosis is a skeletal disorder characterized by reduced bone mineral density (BMD) and micro-architectural deterioration of trabecular or cortical bone that results in increased bone fragility and a substantially higher incidence of bone fracture [3].”
BackgroundEffects of whole-body vibration at different periods on lumbar vertebrae in female rats
Tian, S., Gao, J., Gong, H., Zhang, X., & Wang, S. (2022) · Medical Engineering & Physics · doi:10.1016/j.medengphy.2022.103918 · Cited by 4
Construction of ceRNA regulatory networks for osteoporosis
Chen, H., Wang, H., Liu, X., Li, L., Abudusimu, Y., & Tuoheti, Y. (2023) · Molecular Medicine Reports · doi:10.3892/mmr.2023.13033 · Cited by 5
Moles, R. J., Perry, L., Naylor, J., Ebeling, P. R., Duque, G., Major, G. A. C., White, C., Yates, C. J., Jennings, M. D., Kotowicz, M. A., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072050 · Cited by 5
Wang, C.-C., Liu, H.-C., Lee, M.-T., & Huang, W. (2023) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/21514593231204783 · Cited by 4
Piao, M., Lee, S. H., Li, Y., Choi, J.-K., Yeo, C., & Lee, K. Y. (2023) · Cells · doi:10.3390/cells12212549 · Cited by 5
Chen, J.-J., Chen, I., Wei, C., Lin, S., & Chen, Y. (2023) · Archives of Osteoporosis · doi:10.1007/s11657-023-01357-0 · Cited by 5
Utilization of Romosozumab in Primary Care
Yang, S. H., Mittal, N., Bell, A. L., & Bell, C. E. (2023) · Journal of Pharmacy Technology · doi:10.1177/87551225231220221 · Cited by 3
Ahn, T. R., Yoon, Y. C., Kim, H. S., Kim, K., & Lee, J. H. (2024) · European Journal of Radiology · doi:10.1016/j.ejrad.2024.111323 · Cited by 4
Risk Factors for Fragility Fractures in Chronic Lymphocytic Leukemia
Petty, L., Stephens, D. M., & Sharma, A. (2024) · Cureus · doi:10.7759/cureus.54774 · Cited by 5
“In addition, the presence of FF should prompt initiating osteoporosis treatment, suggesting a lack of awareness of the diagnostic criteria for clinical osteoporosis [18,19].”
BackgroundYue, C., Li, Y., Xu, L., Wang, Q.-Y., Yang, Y.-Y., & Sheng, Z. (2024) · Geriatric Nursing · doi:10.1016/j.gerinurse.2024.06.010 · Cited by 8
Miedany, Y. M. E., Gaafary, M. M. E., Gadallah, N. A., Mahran, S., Abu-Zaid, M. H., Hassan, W. A., & Elwakil, W. (2024) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-024-00270-9 · Cited by 4
Zhang, S., Liu, Y., Yu, W., & Gu, X. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1436486 · Cited by 11
“Among the top 10 most-cited publications (40).”
BackgroundInfluentialThe 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part II
Lee, D. O., Hong, Y. H., Cho, M. K., Choi, Y. S., Chun, S., Chung, Y., Hong, S. H., Hwang, K. R., Kim, J., Kim, H., et al. (2024) · Journal of Menopausal Medicine · doi:10.6118/jmm.300001 · Cited by 7
“Similarly, denosumab is recommended as a first-line treatment by the Endocrine Society [7], the International Osteoporosis Foundation [39], and the National Osteoporosis Foundation (NOF) [40].”
BackgroundA Hip New Standard: Improving Osteoporosis Care with Inpatient Administration of IV Zoledronate
Turner, N., Mayeda, M. S., Lima, B. D., Friess, D., Doung, Y., & Drago, K. (2025) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.24.00766 · Cited by 5
Sánchez‐Rodríguez, D., Bellanger, A., Iconaru, L., Baleanu, F., Hambÿe, A.-S., de Filette, J. M. K., Mugisha, A., Benoit, F., Surquin, M., Bergmann, P., et al. (2025) · European Geriatric Medicine · doi:10.1007/s41999-025-01273-1 · Cited by 7
“Second, the study applies to WHO definition of osteoporosis based on BMD [2, 12].”
InfluentialTheochari, E. G., & Cock, H. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814877-8.00003-9 · Cited by 5
Leslie, W. D., & Majumdar, S. R. (2013) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2013.07.004 · Cited by 4
Itabashi, A., Yoh, K., Chines, A. A., Miki, T., Takada, M., Satō, H., Gorai, I., Sugimoto, T., Mizunuma, H., Ochi, H., et al. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-013-0554-6 · Cited by 4
Distribution of Z-Scores in a University Cohort With an Emphasis on “High” Bone Mineral Density
Morgan, S. L., Peace, F., Lopez‐Ben, R., & Fineberg, N. S. (2010) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2010.07.003 · Cited by 4
The Clinical Use of Denosumab for the Management of Low Bone Mineral Density in Postmenopausal Women
Harris, K. B., Nealy, K. L., Jackson, D. J., & Thornton, P. L. (2012) · Journal of Pharmacy Practice · doi:10.1177/0897190012442061 · Cited by 4
Almeida, A., Atti, V., Agostini, D. C., et al. (2015) · Revista Brasileira de Ortopedia (English Edition) · doi:10.1016/j.rboe.2015.01.004 · Cited by 4
Daswani, B., Desai, M. P., Mitra, S., et al. (2016) · Post Reproductive Health · doi:10.1177/2053369116628722 · Cited by 4
Hinz, L., Freiheit, E., & Kline, G. A. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0134-6 · Cited by 4
Sebastián, A., & Frassetto, L. A. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.04.027 · Cited by 6
Finger Fractures as an Early Manifestation of Primary Hyperparathyroidism Among Young Patients
Ozaki, A., Tanimoto, T. E., Yamagishi, E., et al. (2016) · Medicine · doi:10.1097/md.0000000000003683 · Cited by 4
Osteoporosis and nutrition – a paleopathological insight
Curate, F. (2016) · Antropologia Portuguesa · doi:10.14195/2182-7982_31_2 · Cited by 9
Comparing self-perceived and estimated fracture risk by FRAX® of women with osteoporosis
Baji, P., Gulàcsi, L., Horváth, C., et al. (2016) · Archives of Osteoporosis · doi:10.1007/s11657-016-0300-5 · Cited by 4
Almeida, A., Atti, V., Agostini, D. C., et al. (2014) · Revista Brasileira de Ortopedia · doi:10.1016/j.rbo.2014.02.015 · Cited by 4
Geriatric Orthopaedics: a New Paradigm for Management of Older Patients
Quatman, C. E., & Switzer, J. A. (2017) · Current Geriatrics Reports · doi:10.1007/s13670-017-0197-x · Cited by 4
Yin, Z., Wang, X., Liu, Y., Zhang, Z., Wang, S.-S., & Du, Y. (2017) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.204842 · Cited by 4
Niveles de vitamina D en pacientes con osteoporosis en la ciudad de Neiva, Huila, Colombia
Tovar, A. P., Vásquez, N., & Celemín, C. (2017) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.2.3.95 · Cited by 5
Leadership Training in Endocrinology Fellowship? A Survey of Program Directors and Recent Graduates
True, M. W., Folaron, I., Wardian, J., Colburn, J. A., Sauerwein, T. J., Beckman, D., Kluesner, J. K., Tate, J. M., Graybill, S. D., Davis, R. P., et al. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2016-1062 · Cited by 4
An Evidence-Based Review: The Effects of Malaysian Traditional Herbs on Osteoporotic Rat Models
Mohammad, A., Razaly, N. I., Rani, M. D. M., et al. (2018) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2018.25.4.2 · Cited by 4
Si, L., Eisman, J. A., Winzenberg, T. M., Sanders, K. M., Nguyen, T. V., & Palmer, A. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028365 · Cited by 4
Leslie, W. D., Morin, S. N., Martineau, P., Bryanton, M., & Lix, L. M. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.03.006 · Cited by 8
Acupoint injection treatment for primary osteoporosis
Huang, R., Xu, S., Li, D., & Xie, X. (2019) · Medicine · doi:10.1097/md.0000000000016735 · Cited by 4
“1 associated fracture in their lifetime,([3,4]) which seriously hinders the treatment of osteoporosis patients and increases the mortality rate.([5]) Many osteoporosis patients die within 1 year of a hip fracture.”
BackgroundMacIntyre, J., Drake, P., Garland‐Baird, L., et al. (2019) · Nursing Forum · doi:10.1111/nuf.12385 · Cited by 4
Deal, C. L., Mitlak, B., Wang, Y., Fitzpatrick, L. A., & Miller, P. D. (2019) · Bone Reports · doi:10.1016/j.bonr.2019.100230 · Cited by 5
“Each osteoporotic fracture has a substantial impact on quality of life, morbidity, and mortality, and the incidence of such fractures is rising in the aging populations of developed countries (Marrinan et al., 2015; Watts, 2014; Cosman et al., 2014; Bliuc et al., 2015; Burge et al., 2007; Hernlund et al., 2013).”
Background
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.